High-dose inhaled nitric oxide (iNO200) is associated with reduced oxygen supplementation and a shorter hospital stay among pregnant patients with COVID-19 pneumonia, according to a study published in Obstetrics & Gynecology. Lorenzo Berra, MD, and colleagues examined data from pregnant patients hospitalized with severe bilateral COVID-19 pneumonia between March 2020 and December 2021. Two cohorts were identified: 51 patients receiving standard of care alone (SoC cohort) and 20 receiving iNO200 for 30 minutes twice daily plus SoC (iNO200 cohort). Compared with patients in the SoC cohort, those in the iNO200 cohort had more oxygen supplementation free days 28 days after admission (median, 24 vs 22 days). iNO200 was associated with 63.2% more days free from oxygen supplementation and 59.7% and 63.6% shorter ICU length of stay and hospital length of stay, respectively, in multivariate analyses. There were no adverse events reported with iNO200. “Based on our present findings and the absence of therapeutic trials in pregnant patients with severe pneumonia, randomized controlled trials are warranted to test improved outcomes with iNO200,”Dr. Berra and colleagues wrote.
- Business of Medicine
- Doctor’s Voice